Process and monoclonal antibody for the specific determination of pancreas alpha-amylase in the presence of saliva alpha-amylase

US4939082A · kind A · utility

Assignee

• Boehringer Mannheim GmbH · DE

Inventors

• Kurt Naujoks · Gauting, DE
• Willie Gerhardt · Ritterhude, DE
• Christa Hubner-Parajsz · Tutzing, DE
• Karl Wulff · Weilheim, DE
• Herbert Jungfer · Starnberg, DE
• Helmut Lenz · Tutzing, DE
• Winfried Albert · Eberfing, DE
• August W. Wahlefeld · Hohenpeißenberg, DE

Key dates

• Filing date: Mar 21, 1989
• Grant date: Jul 3, 1990
• Expiry date: Mar 21, 2009

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/809
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

In body fluids containing saliva alpha amylase and pancreatic alpha amylase, pancreatic alpha amylase is determined with a monoclonal antibody which specifically binds but does not inhibit saliva alpha amylase and which has a cross-reactivity of 5% or less toward pancreatic alpha amylase. The monoclonal antibody binds salvia alpha amylase to form a complex which is separated to permit determining pancreatic alpha amylase with an amylase detection system. The complex may be separated by precipitating with a precipitating agent such as an anti-antibody or protein A, or by immobilizing the monoclonal antibody on a solid carrier. The monoclonal antibody is preferably produced by immunizing a host animal with an immunogen containing aluminum hydroxide, Bordatella pertussis and native saliva alpha amylase at least 7 times over a period of at least 9 months, fusing B lymphocytes of the immunized host animal with a transforming agent to produce hybridomas, cloning and culturing the hybridomas, and screening antibodies formed.